The Remarkable Success Of CAR T For Lymphoma 10 Years Later

Ten-year results show a single CAR T infusion can keep many patients with aggressive and slow-growing B-cell lymphomas cancer-free, pointing toward true long-term cures.

ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?

ESLA READ THE FULL ESLA RESEARCH REPORT Business Update ARTEMIS Platform Potential in Treating Extramedullary Disease Extramedullary disease (EMD) remains one of the most significant unresolved ...
NBC Los Angeles

Good PR or obscene? Ads for adult website upsetting Long Beach neighbors

Several controversial advertisements placed on public streets have prompted incessant complaints from Long Beach residents: ...
Nature

€1 million prize awarded for personalized CAR T-cell cancer immunotherapies

“Silly, useless, and a waste of time” were just some of the dismissive remarks from the medical community directed at immunologist-oncologist, Carl June, of the University of Pennsylvania, in ...
The Lancet

IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study

aDepartment of Hematology, Centre for Leading Medicine and Advanced Technologies of Institute of Health and Medicine, The First Affiliated Hospital of University of Science and Technology of China, ...